{"id":25953,"date":"2023-12-12T18:04:55","date_gmt":"2023-12-12T12:34:55","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=25953"},"modified":"2023-12-14T10:04:18","modified_gmt":"2023-12-14T04:34:18","slug":"epcore-nhl-1-trial-analysis","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis","title":{"rendered":"EPCORE NHL-1 Trial Reveals Promising Response Rates for Investigational Follicular Lymphoma Therapy: A Game-Changing Alternative in Focus"},"content":{"rendered":"\n
Date of Abstract presentation<\/td>9th December 2023<\/td><\/tr>
Indications<\/td>Follicular Lymphoma (FL)<\/td><\/tr>
Abstract Number<\/td>1655<\/td><\/tr>
Abstract type<\/td>Poster<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Follicular lymphoma is the second most common form of non-Hodgkin\u2019s lymphoma, which is considered incurable and can be difficult to treat in the R\/R setting. EPCORE NHL-1 is a multi-center trial comprising three Phases\u2014Phase I for dose escalation, Phase IIa expansion, and Phase IIa dose optimization. It is an open-label study assessing the safety and preliminary efficacy of subcutaneous epcoritamab in individuals with relapsed, progressive, or refractory CD20+ mature B-cell non-Hodgkin\u2019s lymphoma (B-NHL), including follicular lymphoma. The findings presented at the ASH 2023 from the pivotal cohort of 128 adult patients showed that, with a median follow-up of 17.4 months, the primary endpoint of the study, the overall response rate (ORR), surpassed the specified efficacy threshold at 82%,<\/strong> accompanied by a 63% complete response (CR) rate and 67% minimal residual disease (MRD) negativity<\/strong>. In addition to that, rapid responses were observed, with a median time to response of 1.4 months and a median time to CR of 1.5 months. Notably, the median progression-free survival (PFS), duration of response, duration of CR, MRD negativity, and overall survival were not reached for patients achieving a CR. Furthermore, a remarkable 85% and 74% of patients in CR sustained their response at 12 and 18 months, respectively. <\/p>\n\n\n\n

Safety outcomes were in line with previous epcoritamab trials, demonstrating overall good tolerability. With a tailored step-up dose approach for follicular lymphoma patients, 40% experienced Grade 1 CRS, 8 percent Grade 2 (no Grade 3 or higher CRS reported),<\/strong> and no Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). This data suggests potential support for outpatient administration. Other notable treatment-related adverse events (>20%) in the pivotal cohort included injection-site reactions (57%), COVID-19 (40%), fatigue (30%), neutropenia (29%), diarrhea (27%), and pyrexia (25%). Lastly, treatment discontinuation due to adverse events occurred in 19% of patients, with Grade 5 adverse events reported in 13 patients (10%).<\/p>\n\n\n\n

KOL Insights<\/strong><\/h2>\n\n\n\n
\n

\u201cDespite treatment advances for patients with follicular lymphoma whose disease has unfortunately progressed, treating relapsed or refractory follicular lymphoma remains highly challenging, particularly in the third-line plus setting. The patients in this trial represent a historically difficult-to-treat patient population. The data presented today are especially notable because they demonstrated high overall and complete response rates for this investigational follicular lymphoma therapy and a preview for its potential as an alternative treatment option.\u201d \u2013Expert Opinion.<\/strong><\/p>\n<\/blockquote>\n\n\n\n

Conclusion<\/strong><\/h2>\n\n\n\n

The findings unveiled in the pivotal Phase I\/II EPCORE NHL-1 trial stand out as noteworthy, showcasing elevated overall and complete response rates for this experimental follicular lymphoma therapy. These results offer a glimpse into its potential as a promising alternative treatment option.<\/p>\n\n\n\n

Refer to the Related Reports for More In-depth Insights<\/strong> – <\/p>\n\n\n\n

\n
\n

Diffuse Large B-cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Marginal Zone Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Acute Lymphocytic Leukemia (ALL) Market<\/a><\/strong><\/p>\n\n\n\n

Myelodysplastic Syndrome Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Pipeline Insight<\/a><\/strong><\/p>\n<\/div>\n\n\n\n

\n

Hodgkin’s lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Mantle Cell Lymphoma Market<\/a><\/strong><\/p>\n\n\n\n

Myelofibrosis Market<\/a><\/strong><\/p>\n\n\n\n

Multiple Myeloma Market<\/a><\/strong><\/p>\n\n\n\n

Follicular Lymphoma Market<\/a><\/strong><\/p>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Date of Abstract presentation 9th December 2023 Indications Follicular Lymphoma (FL) Abstract Number 1655 Abstract type Poster Follicular lymphoma is the second most common form of non-Hodgkin\u2019s lymphoma, which is considered incurable and can be difficult to treat in the R\/R setting. EPCORE NHL-1 is a multi-center trial comprising three Phases\u2014Phase I for dose escalation, […]<\/p>\n","protected":false},"author":6,"featured_media":25976,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[41],"tags":[20413,20004,21526,21525,21534,21533,137,841,927,18834,18833,18921],"industry":[17225],"therapeutic_areas":[17233,17228],"class_list":["post-25953","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snippets","tag-abstracts","tag-american-society-of-hematology","tag-american-society-of-hematology-2023","tag-ash-2023","tag-ash-abstracts","tag-ash-annual-meeting-abstracts","tag-cancer","tag-cancer-research","tag-cancer-treatment","tag-follicular-lymphoma","tag-follicular-lymphoma-market","tag-hematology","industry-pharmaceutical","therapeutic_areas-hematological-disorders","therapeutic_areas-oncology"],"acf":[],"yoast_head":"\nPhase I\/II EPCORE NHL-1 Trial Update for Follicular Lymphoma<\/title>\n<meta name=\"description\" content=\"Findings shows that pivotal Phase I\/II EPCORE NHL-1 trial stand out as noteworthy as an experimental follicular lymphoma therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Phase I\/II EPCORE NHL-1 Trial Update for Follicular Lymphoma\" \/>\n<meta property=\"og:description\" content=\"Findings shows that pivotal Phase I\/II EPCORE NHL-1 trial stand out as noteworthy as an experimental follicular lymphoma therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-12-12T12:34:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-12-14T04:34:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12180212\/epcore-nhl-1-trial-updates.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Phase I\/II EPCORE NHL-1 Trial Update for Follicular Lymphoma","description":"Findings shows that pivotal Phase I\/II EPCORE NHL-1 trial stand out as noteworthy as an experimental follicular lymphoma therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis","og_locale":"en_US","og_type":"article","og_title":"Phase I\/II EPCORE NHL-1 Trial Update for Follicular Lymphoma","og_description":"Findings shows that pivotal Phase I\/II EPCORE NHL-1 trial stand out as noteworthy as an experimental follicular lymphoma therapy.","og_url":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2023-12-12T12:34:55+00:00","article_modified_time":"2023-12-14T04:34:18+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12180212\/epcore-nhl-1-trial-updates.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis","url":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis","name":"Phase I\/II EPCORE NHL-1 Trial Update for Follicular Lymphoma","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12180212\/epcore-nhl-1-trial-updates.png","datePublished":"2023-12-12T12:34:55+00:00","dateModified":"2023-12-14T04:34:18+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd"},"description":"Findings shows that pivotal Phase I\/II EPCORE NHL-1 trial stand out as noteworthy as an experimental follicular lymphoma therapy.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/epcore-nhl-1-trial-analysis#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12180212\/epcore-nhl-1-trial-updates.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12180212\/epcore-nhl-1-trial-updates.png","width":1200,"height":800,"caption":"Phase I\/II EPCORE NHL-1 Trial Update"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/0d96a31a370c143ffdb481d985d7edfd","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f9314f22b8c5b61d496451e91f32488d2457ecb59283b7b2ad7e82d330b47aba?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/arawat"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2023\/12\/12180212\/epcore-nhl-1-trial-updates-300x200.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Snippets - A Small piece of News or Article<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society of Hematology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">American Society Of Hematology 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH 2023<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Cancer Treatment<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/snippets\/\" class=\"advgb-post-tax-term\">Hematology<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Abstracts<\/span>","<span class=\"advgb-post-tax-term\">American Society of Hematology<\/span>","<span class=\"advgb-post-tax-term\">American Society Of Hematology 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH 2023<\/span>","<span class=\"advgb-post-tax-term\">ASH Abstracts<\/span>","<span class=\"advgb-post-tax-term\">ASH Annual Meeting Abstracts<\/span>","<span class=\"advgb-post-tax-term\">Cancer<\/span>","<span class=\"advgb-post-tax-term\">Cancer research<\/span>","<span class=\"advgb-post-tax-term\">Cancer Treatment<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma<\/span>","<span class=\"advgb-post-tax-term\">Follicular Lymphoma Market<\/span>","<span class=\"advgb-post-tax-term\">Hematology<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Dec 12, 2023","modified":"Updated on Dec 14, 2023"},"absolute_dates_time":{"created":"Posted on Dec 12, 2023 6:04 pm","modified":"Updated on Dec 14, 2023 10:04 am"},"featured_img_caption":"Phase I\/II EPCORE NHL-1 Trial Update ","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25953","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=25953"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/25953\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/25976"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=25953"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=25953"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=25953"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=25953"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=25953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}